Page 1 | Search Results | Blood | American Society of Hematology

Skip to Main Content

Skip Nav Destination

1-3 of 3

Sort by

Sort Order Select

Journal Articles

Exploring Alternative Dosing Regimens of Single-Agent Belantamab Mafodotin on Safety and Efficacy in Patients with Relapsed or Refractory Multiple Myeloma: DREAMM-14

Malin Hultcrantz, David Kleinman, Pavandeep Ghataorhe, Astrid McKeown, Wei He, Thomas Ling, Roxanne C Jewell, Joseph Brunner, Julie Byrne, Laurie Eliason, Emma Scott, Joanna Opalinska

Blood (2021) 138 (Supplement 1): 1645.

https://doi.org/10.1182/blood-2021-152224

Published: 2021

Journal Articles

Ocular Health of Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Baseline Data from the DREAMM-2 Trial of Belantamab Mafodotin (Belamaf)

Rakesh Popat, Aikaterini Kazantzi, MD, Asim Farooq, MD, Praneetha Thulasi, MD, Sagar Lonial, MD FACP, Andrzej Jakubowiak, MD PhD, Ashraf Z. Badros, MD, Bennie H. Jeng, MD, Joanna Opalinska, MD, January Baron, MS, Trisha Piontek, BSN, Julie Byrne, PhD, Lynsey Womersley, MSc, Ira Gupta, MD, Simona Degli Esposti, MD

Blood (2020) 136 (Supplement 1): 43–44.

https://doi.org/10.1182/blood-2020-139315

Published: 2020

Journal Articles

Recovery of Ocular Events with Longer-Term Follow-up in the DREAMMM-2 Study of Single-Agent Belantamab Mafodotin (Belamaf) in Patients with Relapsed or Refractory Multiple Myeloma (RRMM)

Sagar Lonial, MD FACP, Ajay Nooka, MDMPH, Praneetha Thulasi, MD, Ashraf Z. Badros, MD, Bennie H. Jeng, MD, Natalie S. Callander, MD, Douglas Sborov, MD MS, Brian E. Zaugg, MD, Rakesh Popat, Simona Degli Esposti, MD, Julie Byrne, PhD, Joanna Opalinska, MD PhD, January Baron, MS, Trisha Piontek, BSN, Ira Gupta, MD, Reza Dana, MD MSc, MPH, Asim Farooq, MD, Andrzej Jakubowiak, MD PhD

Blood (2020) 136 (Supplement 1): 26–27.

https://doi.org/10.1182/blood-2020-140078

Published: 2020